Earlier this month, Flagship Pioneering hinted that another Big Pharma may soon join its growing fleet of collaborators. Now, GSK has sailed into view.

本月早些时候，Flagship Pioneering暗示另一家大型制药公司可能很快就会加入其不断壮大的合作者队伍。现在，葛兰素史克已经进入人们的视野。

The British drugmaker and the venture creation firm will put a combined $150 million upfront towards a respiratory and immunology-focused research project, which will involve Flagship’s portfolio of over 40 biopharma companies. The goal is to identity up to 10 novel medicines and vaccines, for which GSK will have an exclusive option to take forward for further clinical development.

这家英国制药商和这家风险投资公司将为一个以呼吸和免疫学为重点的研究项目预先投入总计1.5亿美元，该项目将涉及Flagship旗下40多家生物制药公司的投资组合。目标是确定多达10种新药和疫苗，葛兰素史克将拥有独家选择来推进进一步的临床开发。

For each program that GSK picks up, Flagship and its companies will be eligible to receive up to $720 million in upfront, development and commercial milestones from GSK, as well as preclinical funding and tiered royalties on sales. That means there is potentially over $7 billion in biobucks for Flagship’s companies to pick up down the line.

对于葛兰素史克选择的每个项目，Flagship及其公司将有资格从葛兰素史克获得高达7.2亿美元的前期、开发和商业里程碑，以及临床前资金和分层销售特许权使用费。这意味着Flagship的公司未来可能有超过70亿美元的生物负载需要购买。

The initial phase will involve identifying and accelerating promising scientific concepts for further research. According to the release, the collaboration will “start” in respiratory and immunology, implying that the partnership could evolve to have a wider therapeutic reach.

初始阶段将涉及识别和加速有前途的科学概念以进行进一步研究。根据发布的消息，合作将在呼吸和免疫学领域“开始”，这意味着合作伙伴关系可能会发展到更广泛的治疗范围。

“Together with Flagship, we will use science and technology to deliver best-in-class innovation at pace,” GSK Chief Scientific Officer Tony Wood, Ph.D., said in a July 29 release. “We look forward to partnering with the talented team at Flagship, and their ecosystem of bioplatform companies, to further accelerate our pipeline and discover practice-changing medicines and vaccines for patients.”

葛兰素史克首席科学官Tony Wood博士表示：“我们将与Flagship合作，利用科学技术同步实现一流的创新。”在7月29日的一份新闻稿中说道。“我们期待与Flagship的才华横溢的团队及其生物平台公司生态系统合作，进一步加快我们的管道，并为患者发现改变实践的药物和疫苗。”

Related An innovation supply chain: Pfizer taps Flagship for 10-program pipeline pact worth $7B in biobucks

相关 创新供应链：辉瑞与Flagship签订价值70亿美元的10个项目管道协议

Flagship and its biotechs have been on a roll when it comes to signing up major players in the pharma and medtech arenas. Last year, Pfizer and Flagship each put down $50 million to build a new pipeline of 10 programs, with the first target being unveiled last month in the red-hot R&D space of obesity.

Flagship及其生物技术公司在与制药和医疗技术领域的主要参与者签约方面一直进展顺利。去年，辉瑞和Flagship各投入5000万美元，建立了一条由10个项目组成的新管道，第一个目标于上个月在火热的肥胖研发领域公布。

Obesity was also at the heart of a $600 million biobucks pact signed by Novo Nordisk and Flagship-founded Metaphore Biotechnologies in May.

肥胖也是诺和诺德和Flagship创立的Metaphore Biotechnologies五月份签署的6亿美元生物学协议的核心。

“Flagship and GSK have a shared focus on delivering breakthrough medicines for patients,” Paul Biondi, general partner, Flagship Pioneering and president, Pioneering Medicines, said in this morning's release.

Flagship普通合伙人兼先锋药品总裁Paul Biondi在今天上午的新闻稿中表示：“Flagship和葛兰素史克共同致力于为患者提供突破性药物。”

“This collaboration is the latest example of Flagship's Innovation Supply Chain Partnership model, which is designed to generate transformational medicines together with our pharma partners by leveraging our ecosystem of first-in-category bioplatforms to create a sustainable source of treatments for patients with the greatest unmet needs,” Biondi added.

“这次合作是Flagship创新供应链合作伙伴关系模式的最新例子，该模式旨在与我们的制药合作伙伴一起生产变革性药物，通过利用我们的同类一流生物平台生态系统，为最大未满足需求的患者创造可持续的治疗来源，”比昂迪补充道。

Earlier this month, Flagship announced a fresh $2.6 billion for its eighth venture fund, with a further $1 billion coming from an array of side funds. At the time, the firm pointed to partnerships with the likes of Pfizer, Thermo Fisher and Samsung as being “core to Flagship's strategy for maximizing value creation and the impact of our companies.” In that same release, Flagship alluded to “other [partnerships] under development.”

本月早些时候，Flagship宣布为其第八只风险基金注入26亿美元，另外10亿美元来自一系列副业基金。当时，该公司指出，与辉瑞、赛默费舍尔和三星等公司的合作伙伴关系是“Flagship最大限度地创造价值和影响力战略的核心”。 在同一份新闻稿中，Flagship提到了“正在开发的其他[合作伙伴关系]”。